GHOSH NILANJAN ET AL: "Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma", BLOOD, vol. 114, no. 22, November 2009 (2009-11), page 1119, XP009145845, & 51ST ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 05 -08, 2009 (B8)

LAPALOMBELLA ROSA ET AL: "Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 13, 15 December 2008 (2008-12-15), pages 5180-5189, XP009145765, ISSN: 0006-4971 (B8)

RICHARDS TIFFANY ET AL: "Advances in treatment for relapses and refractory multiple myeloma", MEDICAL ONCOLOGY (TOTOWA), vol. 27, no. Suppl. 1, June 2010 (2010-06) , pages 25-42, XP009145832, ISSN: 1357-0560 (B8)

WO-A2-2008/037257 (B8)

VAN DER VEER MICHAEL S ET AL: "Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.", HAEMATOLOGICA FEB 2011 LNKD- PUBMED:21109694, vol. 96, no. 2, February 2011 (2011-02), pages 284-290, XP009145823, ISSN: 1592-8721 (B8)

WIERNIK PETER H: "Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).", CURRENT TREATMENT OPTIONS IN ONCOLOGY APR 2009 LNKD- PUBMED:19016330, vol. 10, no. 1-2, April 2009 (2009-04), pages 1-15, XP009145844, ISSN: 1534-6277 (B8)

WO-A2-2007/042309 (B8)

STEVENSON G T: "CD38 as a therapeutic target", MOLECULAR MEDICINE 200611 US LNKD- DOI:10.2119/2006-00082.STEVENSON, vol. 12, no. 11-12, November 2006 (2006-11), pages 345-346, XP009145827, ISSN: 1076-1551 (B8)